Chromosomal Deletions and Cancer: How Lost Genes Create New Treatment Opportunities

When cancer develops, it often does so through the loss of critical genes that normally prevent tumor formation. These tumor suppressor genes act as the body’s internal brakes on uncontrolled cell growth. But when chromosomes break and segments are deleted during cancer progression, the damage isn’t always limited to just one gene. Sometimes, the deletion of a tumor suppressor gene also removes neighboring genes — and this collateral loss can unexpectedly create new vulnerabilities that doctors can now target with precision therapies.

This emerging concept, known as collateral lethality, is reshaping how researchers think about cancer treatment. Instead of focusing solely on replacing lost tumor suppressors — a strategy that has proven difficult — scientists are now exploiting the weaknesses created when nearby genes are deleted along with them. This approach turns a cancer’s genetic instability into a therapeutic advantage.

How Chromosomal Deletions Drive Cancer and Create Targets

Chromosomal deletions are common in many cancers. For example, loss of the short arm of chromosome 17 (17p) frequently occurs in breast, ovarian, and colorectal cancers and often includes the TP53 gene — the most frequently mutated tumor suppressor in human cancer. When TP53 is lost, cells lose a key guardian that helps repair DNA or trigger programmed cell death when damage is too severe.

But in many cases, the deletion extends beyond TP53 to include adjacent genes. One well-studied example is the loss of SMARCA4, a gene involved in chromatin remodeling, which often occurs alongside TP53 deletion in certain lung and ovarian cancers. Research shows that when both genes are lost, cancer cells become dependent on alternative pathways to manage DNA stress — making them uniquely sensitive to inhibitors of those backup systems.

Similarly, in pancreatic cancer, the frequent deletion of SMAD4 on chromosome 18q often includes the neighboring DCC gene. Studies have found that loss of DCC alters how cancer cells respond to netrin-1 signaling, creating a dependency on specific survival pathways that can be blocked with experimental drugs.

These findings illustrate a key principle: the same chromosomal instability that drives cancer can also create Achilles’ heels. By identifying which genes are consistently co-deleted with known tumor suppressors, researchers can predict which backup pathways cancer cells become reliant on — and then design drugs to block those pathways selectively in tumor cells.

From Discovery to Therapy: Targeting Collateral Vulnerabilities

The idea of collateral lethality gained traction after a 2015 study demonstrated that deletion of the tumor suppressor SMAD4 in pancreatic cancer led to vulnerability to inhibition of the protein MAPK — a finding later validated in preclinical models. Since then, similar patterns have emerged across cancer types.

For instance, in glioblastoma, co-deletion of CDKN2A (a tumor suppressor) and MTAP — a gene involved in recycling the nucleotide adenine — creates a metabolic dependency. Cells lacking both genes cannot efficiently salvage adenine and must rely on de novo synthesis. This makes them highly sensitive to inhibitors of PRMT5 or MAT2A, enzymes involved in that pathway. Clinical trials testing MAT2A inhibitors in MTAP-deleted cancers are now underway, with early signs of activity in sarcoma and glioma.

Another example involves the deletion of FHIT, a fragile site tumor suppressor often lost in lung, breast, and esophageal cancers. When FHIT is lost, particularly alongside FRA3B region genes, cancer cells reveal increased sensitivity to certain chemotherapy agents that induce replication stress — suggesting a potential biomarker-guided approach to treatment selection.

These strategies represent a shift from broad cytotoxic therapies to precision approaches that exploit the very genetic chaos that defines cancer. Because the collateral deletions are specific to tumor cells and rarely present in healthy tissues, targeting these vulnerabilities offers the promise of fewer side effects.

Challenges and Future Directions

While the concept of collateral lethality is promising, translating it into widespread clinical use faces hurdles. One challenge is accurately mapping the extent of chromosomal deletions in individual tumors — standard genomic tests may not detect all co-deleted genes, especially if the breakpoints are complex or involve repetitive sequences.

Advances in long-read sequencing and optical genome mapping are improving detection of structural variations, helping researchers and clinicians identify which neighboring genes are truly lost. Developing drugs that target the backup pathways created by these deletions requires deep understanding of cellular metabolism, DNA repair, and signaling networks.

Nonetheless, the pipeline is growing. Several collateral lethality-based targets — including PRMT5, MAT2A, and POLQ — are now in early-phase clinical trials. Biomarker-driven trials that select patients based on specific co-deletion patterns are beginning to show encouraging results, particularly in hard-to-treat cancers like pancreatic adenocarcinoma and tiny cell lung cancer.

As our ability to read cancer genomes improves, so too does our capacity to turn genetic losses into therapeutic gains. The field is moving toward a future where a tumor’s deletion profile doesn’t just predict prognosis — it directly informs which drug is most likely to work.

Key Takeaways

• Chromosomal deletions in cancer often remove tumor suppressor genes along with nearby genes, creating genetic vulnerabilities known as collateral lethality.
• These co-deletions can force cancer cells to rely on backup survival pathways, which can be targeted with specific drugs.
• Examples include MTAP loss leading to sensitivity to MAT2A or PRMT5 inhibitors, and SMAD4 co-deletion creating dependence on MAPK signaling.
• Targeting collateral lethality offers a precision strategy with potential for fewer side effects, as the vulnerabilities are tumor-specific.
• Ongoing clinical trials are testing this approach in sarcoma, glioma, pancreatic cancer, and other malignancies, with early evidence of activity.

Frequently Asked Questions

What is collateral lethality in cancer?

Collateral lethality refers to the phenomenon where the deletion of a tumor suppressor gene during cancer development also removes adjacent genes, creating a dependency on alternative cellular pathways that can be exploited for therapy.

Why can’t we just replace lost tumor suppressor genes like TP53?

While replacing tumor suppressors is a logical idea, delivering functional genes to cancer cells in the body remains a major technical challenge. Current gene delivery methods lack efficiency and specificity, making indirect strategies like targeting collateral vulnerabilities more feasible in the near term.

Are there approved drugs based on collateral lethality today?

As of now, no drugs are approved solely based on collateral lethality biomarkers. Although, several investigational agents targeting pathways like MAT2A, PRMT5, and POLQ are in clinical trials, and some are being tested in biomarker-selected populations (e.g., MTAP-deleted cancers).

How do doctors know if a patient’s tumor has these co-deletions?

Comprehensive genomic profiling using next-generation sequencing can detect chromosomal deletions and identify which genes are lost. Hospitals and cancer centers increasingly use these tests to guide treatment decisions, especially in clinical trials or advanced disease settings.

Is collateral lethality relevant to all cancers?

While the principle applies across cancer types, the specific co-deletions and resulting vulnerabilities vary. It is most studied in cancers with high rates of chromosomal instability, such as pancreatic, ovarian, lung, and colorectal cancers, as well as sarcomas and gliomas.